RxDoctor Payments Data

Eden Etcheverria, PA

Physician Assistant · Youngsville, LANPI 1801314315

Payments from drug & device makers

$4,382in general payments, 2019–2025

Across 208 payments — averaging $21.07 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Sanofi$944
  • Johnson & Johnson$832
  • AbbVie$572
  • Lilly USA, LLC$430
  • Amgen$299
  • E.r. Squibb & Sons, L.L.C.$190
  • plus $1K from 14 others

What the payments were for

  • Food & beverage$4,00691%
  • Education$3769%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,382 in reported general payments places this provider in the 90th percentile of 1,246 physician assistant providers in Louisiana.

See all physician assistant providers in Louisiana

Medicare billing

Part B allowed, 2024
$106,050
Medicare patients
343
Services billed
2,592

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
StelaraUstekinumab35$820,361
Dupixent SyringeDupilumab69$282,375
Cosentyx Sensoready (2 Pens)Secukinumab23$175,518
Dupixent PenDupilumab34$124,498
OtezlaApremilast14$69,884
Tacrolimus219$28,587
Fluorouracil212$13,308
Ketoconazole524$7,044
Triamcinolone Acetonide318$4,411
Pimecrolimus12$3,308
Fluocinonide59$2,784
Hydroxychloroquine Sulfate102$2,652
Metronidazole58$2,237
CiclopiroxCiclopirox Olamine59$2,062
Clindamycin Phosphate81$1,252

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonStelara$832$820,36135 claims
AmgenOtezla$299$69,88414 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,246 physician assistant providers in Louisiana.

Other physician assistant in Youngsville

See the full list for Louisiana

Where these figures come from

Is this you, or does something look wrong? →